Ultragenyx Pharma Q2 Loss Narrows; Lifts FY Revenue Guidance; Stock Up In After-hours

(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) reported that its second quarter net loss narrowed to $131.60 million or $1.52 per share from $159.83 million or $2.25 per share in the prior year.

Quarterly total revenues were $147.03 million, represents 36% growth compared to the same period in 2023.

Analysts polled by Thomson Reuters expected the company to report a loss of $1.69 per share and revenues of $123.18 million for the second quarter. Analysts' estimates typically exclude special items.

The company raised its fiscal year 2024 total revenue guidance to a range of $530 million to $550 million from the prior estimation of $500 million to $530 million. Analysts expected revenue of $513.16 million for fiscal year.

RARE closed Thursday's regular trading at $44.15 down $0.87 or 1.93%. But in the after-hours trading, the stock gained $3.82 or 8.65%.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.